There is a race to fight the spread of Coronavirus, and Symbient is proud to be integral in the current development of 20+ diagnostic cartridges for the assessment of the disease and other diagnostic targets. Thanks to breakthrough advancements in technology over the last 20 years, COVID-19 is being quickly understood and vaccines are now in clinical trials. This is due, in part, to nucleic acid testing (NAT) and rapid genome sequencing practices known as Next Generation Sequencing (NGS) .
At Symbient, developing and producing sample preparation devices and microfluidic cartridges for NAT and NGS is approximately 80% of our business, and is a field we have worked in for over sixteen years. Our services include the design, prototyping, and low volume production of custom diagnostic cartridges and sample collection/transfer devices for universities, medical and biotech companies.
Understanding how such a virus travels, mutates, and affects the human biology is essential to combating it. From a population genetic analyses of 103 sequenced genomes of SARS-CoV-2, researchers have found there to be 2 mutations, thus far. As this is a small sample size, efforts across the world continue in order to gain more understanding. Symbient will continue to support the global effort to diagnose and treat this and similar viruses. If you’re applying for a grant or other funding to develop a diagnostic for COVID-19 or other target, we can provide a letter of support for your grant application.
For more information, click on the button below.